Welcome to our dedicated page for Bridgebio Pharma SEC filings (Ticker: BBIO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
BridgeBio Pharma, Inc. filings document a commercial-stage biopharmaceutical company focused on medicines for genetic conditions, including financial results, product revenue disclosures, program updates, and formal reports on ATTR-CM, LGMD2I/R9, and achondroplasia development programs.
Its SEC record includes Form 8-K disclosures for results of operations, Regulation FD presentations, clinical and regulatory press releases, material agreements, an at-the-market equity distribution agreement, convertible senior notes, and a board-authorized stock repurchase program. Proxy materials address director elections, executive compensation votes, auditor ratification, incentive plan share reserves, governance structure, and stockholder voting matters.
BridgeBio Pharma announced that the FDA has accepted and granted Priority Review to its New Drug Application for oral BBP-418, targeting limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). The FDA set a PDUFA target action date of November 27, 2026 and is not currently planning to hold an advisory committee meeting.
If approved, BBP-418 would be the first and only therapy for people living with LGMD2I/R9 and the first approved treatment for any form of limb-girdle muscular dystrophy, addressing a significant unmet need. In the Phase 3 FORTIFY trial, BBP-418 met all primary and secondary endpoints, with treated patients improving on key measures while placebo patients declined.
BBP-418 has Orphan Drug, Fast Track and Rare Pediatric Disease designations from the FDA and Orphan Drug designation from the EMA. BridgeBio plans additional studies in younger LGMD2I/R9 patients and in related LGMD2M/R13 and LGMD2U/R20 indications.
BridgeBio Pharma, Inc. Chief Executive Officer and director Neil Kumar reported open-market sales of 26,103 shares of common stock on May 21, 2026. The shares were sold at weighted average prices within ranges from $66.81 to $70.97 per share under a pre-arranged Rule 10b5-1 sales plan adopted on March 31, 2025.
Following these transactions, Kumar directly holds 267,174 BridgeBio common shares. In addition, the Kumar Haldea Revocable Trust and the Kumar Haldea Family Irrevocable Trust, for which he serves as co-trustee, hold 4,358,447 and 555,686 shares, respectively, although he disclaims beneficial ownership of those trust-held shares except to the extent of any pecuniary interest.
Issuer filed a Form 144 reporting planned sales of Common Stock under 10b5-1 plans by trusts associated with Kumar Haldea. The filing lists multiple 10b5-1 dispositions of 20,000 shares each on dates including 03/12/2026, 03/13/2026, 04/09/2026, 04/10/2026, 05/07/2026, 05/08/2026, and a restricted stock unit entry dated 05/16/2026. Transactions were executed through Morgan Stanley Smith Barney LLC.
BridgeBio Pharma President and CFO Thomas Trimarchi reported routine equity activity in company stock. On May 18, 2026, he made open-market sales totaling 13,651 shares of common stock at weighted average prices around the mid-$60s per share, under a pre-arranged Rule 10b5-1 sales plan. On May 16, 2026, 22,781 shares were withheld to cover taxes tied to the vesting of 41,193 RSUs, which is not an open-market sale. After these transactions, he directly holds 359,194 shares of BridgeBio common stock.
BridgeBio Pharma, Inc. Chief Executive Officer Neil Kumar reported routine equity compensation activity involving Restricted Stock Units (RSUs) and related tax withholding. On May 16, 2026, RSUs covering 71,215 shares of common stock vested and were converted into shares, as reflected by multiple M-code derivative exercises. A total of 36,236 shares of common stock were disposed of under code F at $66.13 per share to satisfy tax obligations, not as an open-market sale, leaving 269,430 common shares held directly. Kumar also has indirect interests in 4,358,447 common shares held by the Kumar Haldea Revocable Trust and 555,686 shares held by the Kumar Haldea Family Irrevocable Trust, with beneficial ownership of these trust holdings disclaimed except to the extent of any pecuniary interest.
BridgeBio Pharma, Inc. Chief Accounting Officer Maricel Apuli reported a share disposition tied to tax withholding on vested equity awards. On May 16, 2026, 4,714 shares of common stock were withheld at $66.13 per share to satisfy her tax obligation on the vesting of 9,260 RSU-based shares. After this withholding, she directly held 129,401 shares of BridgeBio common stock. This type of transaction is used to cover taxes on compensation-related stock vesting rather than representing an open‑market sale.
BridgeBio Pharma director Scott Randal W. exercised stock options for 10,000 shares of common stock at $16.75 per share and sold 10,000 shares in open-market transactions on May 15, 2026. The sales occurred in multiple trades at weighted average prices around the high‑$60 range under a pre-arranged Rule 10b5-1 sales plan. Following these transactions, he holds 11,589 shares directly and 4,000 shares indirectly through Thinking Bench Capital LLC.
Janus Henderson Group plc filed an amendment to a Schedule 13G reporting beneficial ownership of 13,179,013 shares of BridgeBio Pharma, Inc. Common Stock, representing 6.8% of the class as shown with a 03/31/2026 date line. The filing states the Asset Managers exercise shared voting and dispositive power over these shares (each listed with 13,179,013 votes/ dispositive power) and includes a disclaimer that the Asset Managers do not have rights to dividends or sale proceeds for the managed accounts. The filing was signed by Kristin Mariani as Head of North America Compliance on 5/15/2026 and references Exhibit 99 for Item 7 details.
BridgeBio Pharma has submitted a New Drug Application (NDA) to the FDA for encaleret as a targeted treatment for autosomal dominant hypocalcemia type 1 (ADH1). In the Phase 3 CALIBRATE trial, encaleret met all pre-specified primary and key secondary efficacy endpoints.
At Week 24, 76% of participants on encaleret achieved both serum and urine calcium within target ranges, compared with 4% on conventional therapy at Week 4 (p<0.0001). The company states that encaleret may be eligible for priority review and that it anticipates a potential U.S. launch in early 2027, if approved.
BridgeBio plans additional regulatory and development steps, including a Marketing Authorization Application to the EMA for ADH1 in the second half of 2026, ongoing enrollment of the CALIBRATE-PEDS pediatric ADH1 study, and initiation of the -HP Phase 3 study in chronic hypoparathyroidism in Summer 2026. Encaleret has Fast Track and Orphan Drug designations in multiple regions.